Cargando…
Autoantibodies to Interferons in Infectious Diseases
Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infe...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223187/ https://www.ncbi.nlm.nih.gov/pubmed/37243300 http://dx.doi.org/10.3390/v15051215 |
_version_ | 1785049881557073920 |
---|---|
author | Quiros-Roldan, Eugenia Sottini, Alessandra Signorini, Simona Giulia Serana, Federico Tiecco, Giorgio Imberti, Luisa |
author_facet | Quiros-Roldan, Eugenia Sottini, Alessandra Signorini, Simona Giulia Serana, Federico Tiecco, Giorgio Imberti, Luisa |
author_sort | Quiros-Roldan, Eugenia |
collection | PubMed |
description | Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infections with several agents. For instance, anti-type I interferon autoantibodies are implicated in Coronavirus Disease 19 (COVID-19) pathogenesis and found preferentially in patients with critical disease. However, autoantibodies were also described in the serum of patients with viral, bacterial, and fungal infections not associated with COVID-19. In this review, we provide an overview of anti-cytokine autoantibodies identified to date and their clinical associations; we also discuss whether they can act as enemies or friends, i.e., are capable of acting in a beneficial or harmful way, and if they may be linked to gender or immunosenescence. Understanding the mechanisms underlying the production of autoantibodies could improve the approach to treating some infections, focusing not only on pathogens, but also on the possibility of a low degree of autoimmunity in patients. |
format | Online Article Text |
id | pubmed-10223187 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-102231872023-05-28 Autoantibodies to Interferons in Infectious Diseases Quiros-Roldan, Eugenia Sottini, Alessandra Signorini, Simona Giulia Serana, Federico Tiecco, Giorgio Imberti, Luisa Viruses Review Anti-cytokine autoantibodies and, in particular, anti-type I interferons are increasingly described in association with immunodeficient, autoimmune, and immune-dysregulated conditions. Their presence in otherwise healthy individuals may result in a phenotype characterized by a predisposition to infections with several agents. For instance, anti-type I interferon autoantibodies are implicated in Coronavirus Disease 19 (COVID-19) pathogenesis and found preferentially in patients with critical disease. However, autoantibodies were also described in the serum of patients with viral, bacterial, and fungal infections not associated with COVID-19. In this review, we provide an overview of anti-cytokine autoantibodies identified to date and their clinical associations; we also discuss whether they can act as enemies or friends, i.e., are capable of acting in a beneficial or harmful way, and if they may be linked to gender or immunosenescence. Understanding the mechanisms underlying the production of autoantibodies could improve the approach to treating some infections, focusing not only on pathogens, but also on the possibility of a low degree of autoimmunity in patients. MDPI 2023-05-22 /pmc/articles/PMC10223187/ /pubmed/37243300 http://dx.doi.org/10.3390/v15051215 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Quiros-Roldan, Eugenia Sottini, Alessandra Signorini, Simona Giulia Serana, Federico Tiecco, Giorgio Imberti, Luisa Autoantibodies to Interferons in Infectious Diseases |
title | Autoantibodies to Interferons in Infectious Diseases |
title_full | Autoantibodies to Interferons in Infectious Diseases |
title_fullStr | Autoantibodies to Interferons in Infectious Diseases |
title_full_unstemmed | Autoantibodies to Interferons in Infectious Diseases |
title_short | Autoantibodies to Interferons in Infectious Diseases |
title_sort | autoantibodies to interferons in infectious diseases |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10223187/ https://www.ncbi.nlm.nih.gov/pubmed/37243300 http://dx.doi.org/10.3390/v15051215 |
work_keys_str_mv | AT quirosroldaneugenia autoantibodiestointerferonsininfectiousdiseases AT sottinialessandra autoantibodiestointerferonsininfectiousdiseases AT signorinisimonagiulia autoantibodiestointerferonsininfectiousdiseases AT seranafederico autoantibodiestointerferonsininfectiousdiseases AT tieccogiorgio autoantibodiestointerferonsininfectiousdiseases AT imbertiluisa autoantibodiestointerferonsininfectiousdiseases |